PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33512474-7	2021	Genetic ablation or dasatinib-mediated inhibition of LYN reduced CBL phosphorylation, CBL-PIK3R1 interaction, and PI3K/AKT signaling.	Dasatinib	20-29	Cbl proto-oncogene	Homo sapiens	65-68	
18797457-7	2008	Dasatinib also inhibited ligand-induced binding of EphA2 to the ubiquitin ligase Cbl, and the internalisation and degradation of EphA2, suggesting that these processes are dependent on kinase activity.	Dasatinib	0-9	Cbl proto-oncogene	Homo sapiens	81-84	
33512474-7	2021	Genetic ablation or dasatinib-mediated inhibition of LYN reduced CBL phosphorylation, CBL-PIK3R1 interaction, and PI3K/AKT signaling.	Dasatinib	20-29	Cbl proto-oncogene	Homo sapiens	86-89	
33512474-8	2021	Furthermore, we demonstrated in vitro and in vivo antiproliferative efficacy of dasatinib in CBL-mutant cell lines and primary CMML.	Dasatinib	80-89	Cbl proto-oncogene	Homo sapiens	93-96	
23696637-11	2013	Dasatinib treatment inhibited the elevated phosphorylation of CBL-Y371H and CBL-C384R mutants.	Dasatinib	0-9	Cbl proto-oncogene	Homo sapiens	62-65	
24718698-6	2014	Furthermore, two recent studies showed dasatinib to be effective in inhibiting the in vitro growth of cells from leukemia patients with c-Cbl RING finger and linker domain mutations.	Dasatinib	39-48	Cbl proto-oncogene	Homo sapiens	136-141	
24686085-8	2014	In contrast another SFK inhibitor (dasatinib) which blocks Lyn activity with ATRA co-treatment prevented ATRA-induced c-Cbl phosphorylation and crippled p85 PI3K phosphorylation, indicating Lyn kinase activity is important for ATRA-propelled events potentially regulated by CD38.	Dasatinib	35-44	Cbl proto-oncogene	Homo sapiens	118-123	
24457597-5	2014	Dasatinib induced ER stress which mediated EGFR degradation in a c-cbl-dependent manner.	Dasatinib	0-9	Cbl proto-oncogene	Homo sapiens	65-70	
23696637-11	2013	Dasatinib treatment inhibited the elevated phosphorylation of CBL-Y371H and CBL-C384R mutants.	Dasatinib	0-9	Cbl proto-oncogene	Homo sapiens	76-79	
22787428-8	2012	Lysosome inhibitor reversed dasatinib-induced EGFR down-regulation, and c-cbl activity was increased by dasatinib, indicating that dasatinib-induced EGFR down-regulation might be through c-cbl-mediated lysosome degradation.	Dasatinib	28-37	Cbl proto-oncogene	Homo sapiens	187-192	
23400592-5	2013	Notably, dasatinib, an U.S. Food and Drug Administration-approved multikinase inhibitor that also targets Src family, dramatically attenuated the spontaneous and GM-CSF-induced hypersensitive growth phenotype of mononuclear cells from peripheral blood and bone marrow collected from JMML patients harboring Cbl or other known JMML-associated mutations.	Dasatinib	9-18	Cbl proto-oncogene	Homo sapiens	307-310	
22787428-8	2012	Lysosome inhibitor reversed dasatinib-induced EGFR down-regulation, and c-cbl activity was increased by dasatinib, indicating that dasatinib-induced EGFR down-regulation might be through c-cbl-mediated lysosome degradation.	Dasatinib	104-113	Cbl proto-oncogene	Homo sapiens	72-77	
22787428-8	2012	Lysosome inhibitor reversed dasatinib-induced EGFR down-regulation, and c-cbl activity was increased by dasatinib, indicating that dasatinib-induced EGFR down-regulation might be through c-cbl-mediated lysosome degradation.	Dasatinib	104-113	Cbl proto-oncogene	Homo sapiens	187-192	
22787428-8	2012	Lysosome inhibitor reversed dasatinib-induced EGFR down-regulation, and c-cbl activity was increased by dasatinib, indicating that dasatinib-induced EGFR down-regulation might be through c-cbl-mediated lysosome degradation.	Dasatinib	104-113	Cbl proto-oncogene	Homo sapiens	72-77	
22787428-8	2012	Lysosome inhibitor reversed dasatinib-induced EGFR down-regulation, and c-cbl activity was increased by dasatinib, indicating that dasatinib-induced EGFR down-regulation might be through c-cbl-mediated lysosome degradation.	Dasatinib	104-113	Cbl proto-oncogene	Homo sapiens	187-192